報價延遲最少15分鐘:2025/11/07 13:13 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.035 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.45/-0.09
|
|
企業價值
1.57B
|
| 資產負債 |
|
每股賬面淨值
2.59
|
| 現金流量 |
|
現金流量率
0.00
|
| 損益表 |
|
收益
796.97M
|
|
每股收益
2.45
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/11/07 13:13 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000employees and 18 production sites mainly in Europe and the United States. |
